GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » EV-to-EBITDA

Vertex Pharmaceuticals (WBO:VRTX) EV-to-EBITDA : 20.22 (As of Apr. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vertex Pharmaceuticals's enterprise value is €86,343 Mil. Vertex Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €4,271 Mil. Therefore, Vertex Pharmaceuticals's EV-to-EBITDA for today is 20.22.

The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

WBO:VRTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1099.73   Med: 17.51   Max: 2085.27
Current: 20.07

During the past 13 years, the highest EV-to-EBITDA of Vertex Pharmaceuticals was 2085.27. The lowest was -1099.73. And the median was 17.51.

WBO:VRTX's EV-to-EBITDA is ranked worse than
70.61% of 473 companies
in the Biotechnology industry
Industry Median: 9.22 vs WBO:VRTX: 20.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Vertex Pharmaceuticals's stock price is €367.65. Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €12.883. Therefore, Vertex Pharmaceuticals's PE Ratio for today is 28.54.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Vertex Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Vertex Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals EV-to-EBITDA Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.33 16.96 16.91 14.51 20.51

Vertex Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.51 16.36 17.80 17.38 20.51

Competitive Comparison of Vertex Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's EV-to-EBITDA falls into.



Vertex Pharmaceuticals EV-to-EBITDA Calculation

Vertex Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=86343.127/4270.905
=20.22

Vertex Pharmaceuticals's current Enterprise Value is €86,343 Mil.
Vertex Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €4,271 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vertex Pharmaceuticals  (WBO:VRTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vertex Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=367.65/12.883
=28.54

Vertex Pharmaceuticals's share price for today is €367.65.
Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.883.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Vertex Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (WBO:VRTX) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.